Trends in blood pressure control and treatment among type 2 diabetes with comorbid hypertension in the United States: 1988–2004

Suh, Dong‐Churl; Kim, Chul-Min; Choi, In–Hwan; Plauschinat, Craig; Barone, Joseph A.

doi:10.1097/hjh.0b013e32832d4aee

Cited by 87 publications

(49 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Between NHANES III (1984 to 1992) and NHANES 1999 to 2004, the proportion of patients with DM whose BP was treated increased from 76.5% to 87.8%, and the proportion whose BP was controlled nearly doubled (15.9% to 29.6%). 45 …”

Section: Risk Factor: Diabetes Mellitusmentioning

confidence: 99%

Heart Disease and Stroke Statistics—2011 Update

Roger¹,

Go²,

et al. 2011

View full text Add to dashboard Cite

Summary Each year, the American Heart Association (AHA), in conjunction with the Centers for Disease Control and Prevention, the National Institutes of Health, and other government agencies, brings together the most up-to-date statistics on heart disease, stroke, other vascular diseases, and their risk factors and presents them in its Heart Disease and Stroke Statistical Update. The Statistical Update is a valuable resource for researchers, clinicians, healthcare policy makers, media professionals, the lay public, and many others who seek the best national data available on disease morbidity and mortality and the risks, quality of care, medical procedures and operations, and costs associated with the management of these diseases in a single document. Indeed, since 1999, the Statistical Update has been cited more than 8700 times in the literature (including citations of all annual versions). In 2009 alone, the various Statistical Updates were cited ≈1600 times (data from ISI Web of Science). In recent years, the Statistical Update has undergone some major changes with the addition of new chapters and major updates across multiple areas. For this year’s edition, the Statistics Committee, which produces the document for the AHA, updated all of the current chapters with the most recent nationally representative data and inclusion of relevant articles from the literature over the past year and added a new chapter detailing how family history and genetics play a role in cardiovascular disease (CVD) risk. Also, the 2011 Statistical Update is a major source for monitoring both cardiovascular health and disease in the population, with a focus on progress toward achievement of the AHA’s 2020 Impact Goals. Below are a few highlights from this year’s Update. Death Rates From CVD Have Declined, Yet the Burden of Disease Remains High The 2007 overall death rate from CVD (International Classification of Diseases 10, I00–I99) was 251.2 per 100 000. The rates were 294.0 per 100 000 for white males, 405.9 per 100 000 for black males, 205.7 per 100 000 for white females, and 286.1 per 100 000 for black females. From 1997 to 2007, the death rate from CVD declined 27.8%. Mortality data for 2007 show that CVD (I00–I99; Q20–Q28) accounted for 33.6% (813 804) of all 2 243 712 deaths in 2007, or 1 of every 2.9 deaths in the United States. On the basis of 2007 mortality rate data, more than 2200 Americans die of CVD each day, an average of 1 death every 39 seconds. More than 150 000 Americans killed by CVD (I00–I99) in 2007 were <65 years of age. In 2007, nearly 33% of deaths due to CVD occurred before the age of 75 years, which is well before the average life expectancy of 77.9 years. Coronary heart disease caused ≈1 of every 6 deaths in the United States in 2007. Coronary heart disease mortality in 2007 was 406 351. Each year, an estimated 785 000 Americans will have a new coronary attack, and ≈470 000 will have a recurrent attack. It is estimated that an additional 195 000 silent first myocardial infarctions occur each year. Ap...

show abstract

Section: Risk Factor: Diabetes Mellitusmentioning

confidence: 99%

Heart Disease and Stroke Statistics—2011 Update

Roger¹,

Go²,

et al. 2011

View full text Add to dashboard Cite

show abstract

“…13 Despite data supporting the benefits of lowering BP, most patients with diabetes do not reach evidence-based treatment goals. [13][14][15][16][17] An analysis of the NHANES 2003-2004 data showed that 84% of patients with hypertension and diabetes received antihypertensive treatment, 13 but only 35.3% had BP <130/80 mm Hg. Although this represents an improvement from the 1999-2000 NHANES data, 16 it is still not optimal.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study

Chrysant

Izzo

Kereiakes

et al. 2012

Journal of the American Society of Hypertension

View full text Add to dashboard Cite

“…Recent observations are not encouraging: in the US less than 50% of patients undergoing hypertensive treatment reach the target and the percentage is even lower in high risk patients [1]. A recent study carried out by Dr. Volpe in Italy on 50,000 subjects in several Italian regions, has proved how in treated patients, only 1/5 of the hypertensive ones arrives at pressure values b 140/90 mm Hg and, among these, only half the cases reached the target blood pressure [2].…”

Section: Aldosterone Receptor Blocker and Hypertension: Why When?mentioning

confidence: 98%

The role of aldosterone receptor blocker therapy in hypertension and heart failure

Santese

Stefanio

Belletti

et al. 2015

IJC Metabolic & Endocrine

View full text Add to dashboard Cite

The aldosterone receptor blocker therapy as an "add-on" to hypotensive therapy is an excellent therapeutic strategy that has proved to be particularly effective in treating refractory hypertension, hypertension with organ damage and overweight hypertensive patients. Aldosterone receptor blockers are extremely useful in inhibiting hormonal activation linked with heart failure: they have cardioprotective effects not only during full-blown heart failure, but also in its early stages, and this effect can be observed even more frequently in heart failures with metabolic syndrome. The use of molecules such as canrenone with a favorable tolerability profile ensures a better tolerability ratio by providing benefits linked to fewer drug interactions, lower incidence of side effects and improved therapy adherence.

show abstract

Trends in blood pressure control and treatment among type 2 diabetes with comorbid hypertension in the United States: 1988–2004

Abstract: Aggressive public health efforts are needed to improve BP control in type 2 diabetic patients with hypertension.

Cited by 87 publications

References 38 publications

Heart Disease and Stroke Statistics—2011 Update

Heart Disease and Stroke Statistics—2011 Update

Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study

The role of aldosterone receptor blocker therapy in hypertension and heart failure

Contact Info

Product

Resources

About